Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCGR | P47871 | 12/20 | 0.82 |
| ▸ | GLP1R | P43220 | 2/20 | 0.60 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.60 |
| ▸ | GCG | P01275 | 11/20 | 0.57 |
| ▸ | GIPR | P48546 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1765492 | 0.95 | GCGR (0.88) | GCGRGLP1RCHRM5GCGGIPR | |
| SCHEMBL1765608 | 0.92 | GCGR (0.71) | GCGRGLP1RCHRM5GCGGIPR | |
| SCHEMBL19197053 | 0.92 | GCGR (0.78) | GCGRGLP1RCHRM5GCG | |
| SCHEMBL1765321 | 0.91 | GCGR (0.82) | GCGRGLP1RCHRM5GCGGIPR | |
| SCHEMBL1765818 | 0.91 | GCGR (0.74) | GCGRGLP1RCHRM5GCGGIPR | |
| SCHEMBL1765400 | 0.91 | GCGR (0.77) | GCGRGLP1RCHRM5GCG | |
| SCHEMBL1765410 | 0.90 | GCGR (0.75) | GCGRGLP1RCHRM5GCG | |
| Adomeglivant SCHEMBL1765782 | 0.90 | GCGR (1.00) | GCGRGLP1RCHRM5GCGGIPR | |
| Adomeglivant SCHEMBL29379087 | 0.90 | GCGR (1.00) | GCGRGLP1RCHRM5GCGGIPR | |
| SCHEMBL1765647 | 0.89 | GCGR (0.65) | GCGRGLP1RCHRM5GCGGIPR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111184706-B | Active medicine for preventing and treating cholecystitis and application thereof | 牡丹江医学院 | 2020-11-17 | — | — | CN | claimed |
| CN-111184706-A | Active medicine for preventing and treating cholecystitis and application thereof | 牡丹江医学院 | 2020-05-22 | — | — | CN | claimed |
| US-8609892-B2 | Glucagon receptor antagonists, preparation and therapeutic uses | ELI LILLY AND COMPANY (US) | 2013-12-17 | — | — | US | claimed |
| US-20110124648-A1 | GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2011-05-26 | — | — | US | claimed |
| US-20100324140-A1 | GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2010-12-23 | — | — | US | claimed |
| EP-2159221-A1 | Glucagon receptor antagonists, preparation and therapeutic uses | Eli Lilly & Company (US) | 2010-03-03 | — | — | EP | claimed |
| EP-1758853-B1 | GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | LILLY CO ELI (US) | 2010-01-20 | — | — | EP | claimed |
| US-20070249688-A1 | Glucagon Receptor Antagonists, Preparation and Therapeutic Uses | ELI LILLY AND COMPANY (US) | 2007-10-25 | — | — | US | claimed |
| EP-1758853-A1 | GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2007-03-07 | — | — | EP | claimed |
| WO-2005123668-A1 | GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2005-12-29 | — | — | WO | claimed |
| EP-3974413-A1 | ANTIDIABETIC SUBSTITUTED HETEROARYL COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2022-03-30 | — | — | EP | disclosed |
| EP-3082786-B1 | ANTIDIABETIC SUBSTITUTED HETEROARYL COMPOUNDS | MERCK SHARP & DOHME (US) | 2021-10-27 | — | — | EP | disclosed |
| US-11077092-B2 | Methods of treating diabetes by administering a glucagon receptor antagonist in combination with a cholesterol absorption inhibitor | MERCK SHARP & DOHME CORP. (US) | 2021-08-03 | — | — | US | disclosed |
| CN-111184706-B | Active medicine for preventing and treating cholecystitis and application thereof | 牡丹江医学院 | 2020-11-17 | — | — | CN | disclosed |
| CN-111184706-B | Active medicine for preventing and treating cholecystitis and application thereof | 牡丹江医学院 | 2020-11-17 | — | — | CN | disclosed |
| US-20070249688-A1 | Glucagon Receptor Antagonists, Preparation and Therapeutic Uses | ELI LILLY AND COMPANY (US) | 2007-10-25 | — | — | US | disclosed |
| US-20070249688-A1 | Glucagon Receptor Antagonists, Preparation and Therapeutic Uses | ELI LILLY AND COMPANY (US) | 2007-10-25 | — | — | US | disclosed |
| US-20070249688-A1 | Glucagon Receptor Antagonists, Preparation and Therapeutic Uses | ELI LILLY AND COMPANY (US) | 2007-10-25 | — | — | US | disclosed |
| EP-1758853-A1 | GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2007-03-07 | — | — | EP | disclosed |
| WO-2005123668-A1 | GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2005-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11077092-B2 | Methods of treating diabetes by administering a glucagon receptor antagonist in combination with a cholesterol absorption inhibitor | GLP1R, GCGR, GIPR | GCGR 2/4885GLP1R 1/4885CHRM5 1270/4885 |
| US-20110124648-A1 | GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | GLP1R, GCGR, GIPR | GCGR 2/4885GLP1R 1/4885CHRM5 845/4885 |
| US-20070249688-A1 | Glucagon Receptor Antagonists, Preparation and Therapeutic Uses | GLP1R, GCGR, GIPR | GCGR 2/4885GLP1R 1/4885CHRM5 845/4885 |
| US-20100324140-A1 | GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | GLP1R, GCGR, GIPR | GCGR 2/4885GLP1R 1/4885CHRM5 845/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.